Polarean

Polarean Imaging Plc is a medical imaging technology company based in London, UK, focused on enhancing pulmonary medicine through advanced MRI technology. Founded in 2011, Polarean operates internationally, including in the United States. The company specializes in developing hyperpolarized MRI contrast agents and related drug-device combination products that enable non-invasive, radiation-free imaging of lung function. The flagship product, XENOVIEW™, is the first FDA-approved hyperpolarized xenon-129 MRI contrast agent. It allows for detailed visualization of ventilation, gas exchange, and pulmonary vasculature in the lungs, addressing the needs of over 500 million patients with chronic respiratory diseases. Polarean also offers gas polarizer devices, MRI radiofrequency coils compatible with major MRI systems, and ancillary instruments to support biomedical imaging research and clinical applications. Polarean's strategy includes fostering research collaborations and facilitating clinical adoption to enhance the market presence of XENOVIEW and its technologies, targeting healthcare providers and researchers in the field of pulmonary medicine.

• Employees29
• Founded2011
• Annual Revenue$2418000
• Total Funding$25224410